Safety Study for a Gamma Delta T Cell Product Used with Low Dose Radiotherapy in Patients with Locally Advanced or Metastatic NSCLC or Solid Tumors with Bone Metastases

Inclusion Criteria:

• Signed and dated informed consent form.

• Male or female, > 18 years old.

• Minimum body weight of 50 kilograms (kg).

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

• Histologically or cytologically confirmed locally advanced or metastatic NSCLC orlocally advanced or metastatic solid tumor with bone metastasis

• Progressed on SOC therapy including platinum-based chemotherapy and immunecheckpoint inhibitors (NSCLC), and are not a candidate for further standardanti-neoplastic therapy and/or have exhibited intolerance to and/or declinedclinically applicable salvage therapies, and/or have declined therapy.

• Genomic screening, with tumors with known actionable molecular alterations, such asEGFR, ALK, ROS-1, BRAF, RET, MET, and KRAS etc., must have progressed on appropriatetarget-directed molecular therapy.

• At least one measurable target lesion based on RECIST v1.1 confirmed by radiologicalimaging. Participants with isolated bone metastases are eligible for enrollment arenot required to have measurable disease

• All toxicity associated with previous treatments are recovered to CTCAE grade of ≤1,except for continuing alopecia.

• Adequate hematopoietic, hepatic and renal function

• Agree to adequate contraception for up to 120 days after the last dose of studydrug.

• Negative serum pregnancy test for women of childbearing potential

• All primary and metastatic disease sites are amenable to LDRT

• For solid tumors with bone metastases subjects (Part 2 Cohort B): receivingzoledronic acid for solid tumors with bone metastases

Exclusion Criteria:

• Chemotherapy, investigational, and/or check-point inhibitor therapy within the 30days prior to study Day 1.

• Major surgery, except for vascular access placement, within the 30 days prior tostudy Day 1.

• Active autoimmune disease requiring immunosuppressive therapy.

• Infection requiring systemic treatment within 30 days prior to study Day 1.

• History of peritoneal effusion (ascites), pericardial, or pleural effusions/nodules.

• Uncontrolled hypertension, history of arrhythmia including atrial fibrillation,unstable angina, decompensated congestive heart failure, cardiac ejection fraction ≤ 50%, myocardial infarction, or marked baseline prolonged QT/QTc intervals.

• Human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C detection.

• Participation in the treatment portion of a clinical trial or completed a clinicaltrial within the 30 days prior to the first dose of KB-GDT-01.

• Presence of any condition that may, in the opinion of the Investigator, render thepatient inappropriate from participating in the study.

• Breastfeeding or pregnant female, or patient is expecting to conceive or fatherchildren during the study.

• Allergy or intolerance to any of the study product ingredients or excipients.

• Live vaccines administered within 30 days prior to study Day 1.

• Individuals lacking capacity to consent for themselves.

• Superior vena cava obstruction

• Prior radiation therapy to a selected LDRT treatment site </= 30 days prior to Day